Supernus Pharmaceuticals, Inc. (SUPN) Future Price to Earnings

Official company branding of supernus.com (SUPN)

Supernus Pharmaceuticals (SUPN) maintains a robust liquidity reserve driven by high margins on its neurological drugs. The company is building a comprehensive ecosystem for CNS disorder therapy, establishing itself as a key partner for physicians. The issuer's forward P/E illustrates the market valuation trend relative to expected earnings, where 7.60 captures the magnitude of this parameter. Growth is constrained by stringent FDA oversight and high patent requirements within the psychiatry sector.

SUPN - Supernus Projected Price to Earnings Ratio over the range 07/04/2022 - 11/16/2026

Supernus (SUPN) - metric breakdowns and financial figures

Comprehensive company analysis:SUPN Supernus Corp
Signature product of supernus.com

Forward P/E values share prices relative to projected net income, allowing investors to determine the extent of an asset's overbought status based on future cash flows. By analyzing the forward P/E of Supernus Pharmaceuticals (SUPN), one can confirm the stability of the valuation, as a diversified distribution system for neurological drugs minimizes operational risks and ensures revenue predictability.

Main competitors

Forward P/E Multiple BIIB|NBIX - Projected Price to Earnings Ratio|Forward P/E Multiple RGC (Regencell Bioscience Ltd)|Market Cap to Projected Earnings axsome.com (AXSM)|ACADIA Pharmaceuticals Inc - Forward P/E Multiple|Projected Price to Earnings Ratio Xenon Pharmaceuticals Inc.|Viking Therapeutics (VKTX) - Future Price to Earnings|CPRX (Catalyst Pharmaceuticals) - Future Price to Earnings|DNLI (denalitherapeutics.com) - Forward P/E Multiple|Price to Future Earnings Ratio HRMY (Harmony Biosciences Holdings, Inc.)|Forward P/E Multiple BHVN|AMLX (Amylyx Pharmaceuticals Inc) - Future Price to Earnings Multiple|Forward P/E Multiple TRVI (Trevi Pharma)|PRAX (Praxis Corp) - Price to Expected Earnings Ratio|anavex.com - Forward P/E Multiple|Future Price to Earnings Multiple CBLL (CeriBell, Inc.)|PRTA: Forward P/E Multiple|Price to Future Earnings Ratio ALEC|ANNX (Annexon Biosciences Inc.) - Forward P/E Multiple|omeros.com - Price to Expected Earnings Ratio|Future Price to Earnings Neurogene (NGNE)|Market Cap to Projected Earnings AC Immune SA|Forward P/E Multiple VYGR (voyagertherapeutics.com)|Forward P/E Multiple Neumora NMRA|Scilex Holding - Forward P/E Multiple|Projected Price to Earnings Ratio Tevogen Bio Inc.|Alpha Cognition (ACOG) - Future Price to Earnings|cogrx.com (CGTX) - Forward P/E Multiple|Future Price to Earnings Inhibikase Therapeutics|Cassava (SAVA) - Market Cap to Projected Earnings|Future Price to Earnings Assertio Therapeutics (ASRT)|Market Cap to Projected Earnings Coya|Vistagen - Projected Price to Earnings|Future Price to Earnings Multiple OVID|Acumen Pharmaceuticals Inc. - Forward P/E Multiple|Projected Price to Earnings Ratio CervoMed Inc|ATHE: Forward P/E Multiple|Projected Price to Earnings Clene Nanomedicine|Future Price to Earnings PepGen Corp|Jupiter Neurosciences (JUNS) - Market Cap to Projected Earnings|Future Price to Earnings Relmada Therapeutics, Inc. (RLMD)|ANVS - Projected Price to Earnings Ratio|gracetx.com - Projected Price to Earnings|AIFF: Price to Future Earnings Ratio|Klotho Neurosciences - Forward P/E Multiple|NRSN (NeuroSense Therapeutics Ltd.) - Price to Future Earnings Ratio|Reviva Pharmaceuticals (RVPH) - Future Price to Earnings|MTVA (MetaVia Inc.) - Future Price to Earnings|Future Price to Earnings NeurAxis, Inc|Future Price to Earnings HSDT|Forward P/E Multiple PASG|Market Cap to Projected Earnings Neuphoria Therapeutics, Inc.|minervaneurosciences.com - Projected Price to Earnings|Forward P/E Multiple Athira ATHA|Addex Therapeutics - Forward P/E Multiple|ALZN - Forward P/E Multiple|Cyclerion (CYCN) - Future Price to Earnings|Protagenic (PTIX) - Forward P/E Multiple|Future Price to Earnings Pasithea|Price to Future Earnings Ratio CRGT (Cortigent)|Future Price to Earnings Avenue Therapeutics (ATXI)|BCLI - Projected Price to Earnings Ratio|Forward P/E Multiple CARA (Cara Therapeutics Inc)|CHRO - Projected Price to Earnings|ELYM: Projected Price to Earnings|Market Cap to Projected Earnings Intra-Cellular Therapies, Inc. ITCI|Longboard Pharma (LBPH) - Future Price to Earnings|Marinus - Future Price to Earnings Multiple|Future Price to Earnings NKGen Biotech Inc|NRBO: Future Price to Earnings Multiple|Projected Price to Earnings SAGE (Sage Therapeutics, Inc.)|Market Cap to Projected Earnings Neurotrope|Future Price to Earnings Trevena, Inc. TRVN|Vigil Neuroscience (VIGL) - Projected Price to Earnings Ratio|WENA: Projected Price to Earnings|Future Price to Earnings Multiple CERE (Cerevel Therapeutics)